Mesalazine allergy and an attempt at desensitization therapy in patients with inflammatory bowel disease
Abstract Mesalazine is a key drug used for remission induction and maintenance therapy in inflammatory bowel disease (IBD). We sometimes encounter patients who develop allergic reactions to the drug and inevitably discontinue treatment. Of 692 patients who received mesalazine for IBD between 2014 an...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2020-12-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-020-79207-z |
| _version_ | 1818754041099845632 |
|---|---|
| author | Satohiro Matsumoto Hirosato Mashima |
| author_facet | Satohiro Matsumoto Hirosato Mashima |
| author_sort | Satohiro Matsumoto |
| collection | DOAJ |
| description | Abstract Mesalazine is a key drug used for remission induction and maintenance therapy in inflammatory bowel disease (IBD). We sometimes encounter patients who develop allergic reactions to the drug and inevitably discontinue treatment. Of 692 patients who received mesalazine for IBD between 2014 and March 2020, 33 diagnosed with mesalazine allergy (43 episodes) were included, and their clinical manifestations were evaluated. For ten patients undergoing desensitization therapy, therapeutic outcomes were evaluated. The incidence of mesalazine allergy was 4.8%. The time from the start of oral medication to allergy onset was 10 ± 5 days for the first allergic attack and 2 ± 1 days for the second and subsequent allergic attacks. The observed clinical symptoms included fever (93%), diarrhea (26%), abdominal pain (23%), and bloody stool (12%). Drug-induced lymphocyte stimulation test was performed in 85% of the patients (28/33), and the sensitivity was 51%. Desensitization therapy with a time-dependent mesalazine granule formulation was successful in nine of the ten patients (90%), allowing them to receive 2000 mg or more of the drug. Fever was a common allergic symptom, and its presence appeared to be useful for distinguishing mesalazine allergy from exacerbation of the primary disease. Desensitization therapy was useful in patients with mesalazine allergy. |
| first_indexed | 2024-12-18T05:16:56Z |
| format | Article |
| id | doaj.art-a50c4d8aa4dc4df286985a54519ff870 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-12-18T05:16:56Z |
| publishDate | 2020-12-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-a50c4d8aa4dc4df286985a54519ff8702022-12-21T21:19:45ZengNature PortfolioScientific Reports2045-23222020-12-011011710.1038/s41598-020-79207-zMesalazine allergy and an attempt at desensitization therapy in patients with inflammatory bowel diseaseSatohiro Matsumoto0Hirosato Mashima1Department of Gastroenterology, Saitama Medical Center, Jichi Medical UniversityDepartment of Gastroenterology, Saitama Medical Center, Jichi Medical UniversityAbstract Mesalazine is a key drug used for remission induction and maintenance therapy in inflammatory bowel disease (IBD). We sometimes encounter patients who develop allergic reactions to the drug and inevitably discontinue treatment. Of 692 patients who received mesalazine for IBD between 2014 and March 2020, 33 diagnosed with mesalazine allergy (43 episodes) were included, and their clinical manifestations were evaluated. For ten patients undergoing desensitization therapy, therapeutic outcomes were evaluated. The incidence of mesalazine allergy was 4.8%. The time from the start of oral medication to allergy onset was 10 ± 5 days for the first allergic attack and 2 ± 1 days for the second and subsequent allergic attacks. The observed clinical symptoms included fever (93%), diarrhea (26%), abdominal pain (23%), and bloody stool (12%). Drug-induced lymphocyte stimulation test was performed in 85% of the patients (28/33), and the sensitivity was 51%. Desensitization therapy with a time-dependent mesalazine granule formulation was successful in nine of the ten patients (90%), allowing them to receive 2000 mg or more of the drug. Fever was a common allergic symptom, and its presence appeared to be useful for distinguishing mesalazine allergy from exacerbation of the primary disease. Desensitization therapy was useful in patients with mesalazine allergy.https://doi.org/10.1038/s41598-020-79207-z |
| spellingShingle | Satohiro Matsumoto Hirosato Mashima Mesalazine allergy and an attempt at desensitization therapy in patients with inflammatory bowel disease Scientific Reports |
| title | Mesalazine allergy and an attempt at desensitization therapy in patients with inflammatory bowel disease |
| title_full | Mesalazine allergy and an attempt at desensitization therapy in patients with inflammatory bowel disease |
| title_fullStr | Mesalazine allergy and an attempt at desensitization therapy in patients with inflammatory bowel disease |
| title_full_unstemmed | Mesalazine allergy and an attempt at desensitization therapy in patients with inflammatory bowel disease |
| title_short | Mesalazine allergy and an attempt at desensitization therapy in patients with inflammatory bowel disease |
| title_sort | mesalazine allergy and an attempt at desensitization therapy in patients with inflammatory bowel disease |
| url | https://doi.org/10.1038/s41598-020-79207-z |
| work_keys_str_mv | AT satohiromatsumoto mesalazineallergyandanattemptatdesensitizationtherapyinpatientswithinflammatoryboweldisease AT hirosatomashima mesalazineallergyandanattemptatdesensitizationtherapyinpatientswithinflammatoryboweldisease |